Gastroesophageal reflux disease (GERD) is caused by an abnormal reflux of gastric contents into the esophagus. According to the presence of esophageal mucosal breaks; GERD can be divided into two groups, erosive esophagitis and nonerosive reflux disease (NERD).
The term “erosive esophagitis,” which denotes esophageal mucosal erosive changes, has several synonyms: recurrent, reflux, regurgitant, peptic and marginal esophagitis. The term “erosive esophagitis,” is used for it covers mucosal changes other than erosion or ulceration and occurs without reflux or peptic activity.
DelveInsight’s “Erosive Esophagitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Erosive Esophagitis , historical and forecasted epidemiology as well as the Erosive Esophagitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Click here and get access to free sample pages of the Erosive Esophagitis Market Report 2032.
Erosive Esophagitis Disease Overview
Erosive esophagitis is diagnosed based on the Los Angeles classification and was divided into two categories: mild (grades A and B) and severe (grades C and D).
Patients with GERD with the typical reflux syndrome associated with erosive esophagitis and hiatal hernia can have mucosal eosinophilia, which often is confined to the distal esophagus. It is not clear what proportion of patients with GERD present with these features, but it is likely to be less than 10%.” In the same study, it was found that from 2003 to 2006, there were approximately 10,570 hospital admissions annually for erosive esophagitis.
The DelveInsight Erosive Esophagitis market report gives a thorough understanding of Erosive Esophagitis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.
Erosive Esophagitis Epidemiology
The most commonly encountered predisposing factors for Erosive Esophagitis are those related to defects at the esophagogastric junction, such as esophageal hiatal hernia, anatomic variants (short esophagus, intrathoracic stomach, direct esophagogastric junction), and physiologic dysfunction or deglutinative “chalasia“. A total of 23 contributing factors have been encountered, the most prominent of which are hyperacidity, hypersecretion, changes in esophagogastric tonicity, increase in intragastric pressure, and mucosal trauma.
- In persons with GERD symptoms, about 20% are found to have erosive esophagitis, while ulcers or structures are found in less than 5% of all patients with erosive esophagitis.
Request for free sample pages of the report: https://www.delveinsight.com/sample-request/erosive-esophagitis-market
Erosive Esophagitis Drug Chapters
The dynamics of the Erosive Esophagitis market is anticipated to change in the coming years owing to the approval of the upcoming therapy. Key players, such as Takeda, Phathom Pharmaceutical, Ironwood Pharma, Daewoong Pharmaceutical, Luoxin Pharmaceutical, and others are involved in developing a drug based on a novel class of P-CABs.
Erosive Esophagitis Market Outlook
The spectrum of GERD ranges from nonerosive to erosive or complicated disease (ulcer, columnar metaplasia, and stricture), each of which is thought likely to progress if either left untreated or not treated adequately. The goals of treating GERD are to resolve symptoms, heal esophagitis, and prevent complications. Treatment options include lifestyle modifications, medical management with antacids and antisecretory agents, and mechanical therapies.
Expected launch of upcoming therapies shall fuel the growth of the Erosive Esophagitis market during the forecast period, i.e., 2020–2032.
Table of contents
1 Key Insights
2 Executive Summary of Erosive Esophagitis
3 Erosive Esophagitis Market Overview at a Glance
4 Disease Background and Overview: Erosive Esophagitis
5 Case Reports
6 Erosive Esophagitis Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Erosive Esophagitis Treatment and Medical Practices
11 Unmet needs12 Erosive Esophagitis Marketed Drugs
13 Erosive Esophagitis Emerging Drugs
14 Erosive Esophagitis 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Erosive Esophagitis Market Drivers
19 Erosive Esophagitis Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
23 DelveInsight Capabilities
25 About DelveInsight
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States